Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Nature carves colossal snowman in Siberia | Space photo of the day for Jan. 2, 2026 - 2Inn The executives: A Remunerating Profession Decision for Energetic People
- 3‘And then we saw the little head.’ Scientists witness rare sperm whale birth
- 4Health insurance premiums rose nearly 3x the rate of worker earnings over the past 25 years
- 5Exhaustive Experiences into Prudent Senior Living in the UK
- Scientists reveal earliest evidence for shifting of Earth’s crust
- Mobility exercises are an important part of fitness as we age. Here are some tips
- Ultra-Orthodox protests erupt across Israel on haredi IDF enlistment day
- Netanyahu expects Iran's leadership to fall
- 6 Arranging Administrations to Change Your Open air Space
- Eli Lilly weight-loss drug appears to suppress binge-eating signal, small study finds
- Chevron Says Damage at Wheatstone LNG Will Hamper Restart
- Island Travel Guide: Must-Visit Objections for 2024
- Transform the daily grind to make life more interesting – a philosopher shares 3 strategies to help you attain the good life
